.. Epidémiologie-de-la-cohorte-de-diabétiques, 59 3.2. Antécédents familiaux de diabète selon la tolérance glucidique, p.59

.. Type-de-nutrition-selon-la-tolérance-glucidique, Etat respiratoire, nutritionnel et statural selon la tolérance glucidique, p.61

.. Intérêt-de-la-mesure-continue-du-glucose, Intérêt de l'initiation d'un traitement en phase pré-diabétique, p.65

B. Delaisi, Actualit??s dans la mucoviscidose, Revue de Pneumologie Clinique, vol.69, issue.4, pp.225-233, 2013.
DOI : 10.1016/j.pneumo.2013.05.008

G. Bellis, L. Lemonnier, and M. Sponga, Registre français de la mucoviscidose-bilan des données, 2012.

A. Moran, J. Dunitz, B. Nathan, A. Saeed, B. Holme et al., Cystic Fibrosis-Related Diabetes: Current Trends in Prevalence, Incidence, and Mortality, Diabetes Care, vol.32, issue.9, pp.1626-1657, 2009.
DOI : 10.2337/dc09-0586

R. Singer, Cystic fibrosis mortality: registry data of cystic fibrosis, J Insur Med, vol.29, pp.233-242, 1997.

A. Adler, B. Shine, C. Haworth, L. Leelarathna, and D. Bilton, Hyperglycemia and Death in Cystic Fibrosis-Related Diabetes, Diabetes Care, vol.34, issue.7, pp.1577-1585, 2011.
DOI : 10.2337/dc10-2289

A. Moran, C. Brunzell, R. Cohen, M. Katz, B. Marshall et al., Clinical Care Guidelines for Cystic Fibrosis-Related Diabetes: A position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society, Diabetes Care, vol.33, issue.12, pp.2697-708, 2010.
DOI : 10.2337/dc10-1768

S. Française-de-la-mucoviscidose, Groupe de travail Diabète, 2010.

K. Mohan, K. Israel, H. Miller, R. Grainger, M. Ledson et al., Long-Term Effect of Insulin Treatment in Cystic Fibrosis-Related Diabetes, Respiration, vol.51, issue.2, pp.181-187, 2008.
DOI : 10.1136/bmj.311.7006.655

A. Moran, K. Pillay, D. Becker, and C. Acerini, Management of cystic fibrosis-related diabetes in children and adolescents, Pediatric Diabetes, vol.358, issue.Suppl. 677, pp.65-76, 2014.
DOI : 10.1056/NEJMoa0707943

A. Moran, D. Becker, S. Casella, P. Gottlieb, M. Kirkman et al., Epidemiology, Pathophysiology, and Prognostic Implications of Cystic Fibrosis-Related Diabetes: A technical review, Diabetes Care, vol.33, issue.12, pp.2677-83, 2010.
DOI : 10.2337/dc10-1279

L. Dobson, C. Sheldon, and A. Hattersley, Conventional measures underestimate glycaemia in cystic fibrosis patients, Diabetic Medicine, vol.118, issue.7, pp.691-697, 2004.
DOI : 10.1016/S0022-3476(05)80032-0

F. Moreau, M. Weiller, V. Rosner, L. Weiss, M. Hasselmann et al., Continuous Glucose Monitoring in Cystic Fibrosis Patients According to the Glucose Tolerance, Hormone and Metabolic Research, vol.40, issue.07, pp.502-508, 2008.
DOI : 10.1055/s-2008-1062723

K. Konrad, N. Scheuing, K. Badenhoop, M. Borkenstein, B. Gohlke et al., Cystic fibrosisrelated diabetes compared with type 1 and type 2 diabetes in adults, Diabetes Metab. Res. Rev, vol.29, pp.568-75, 2013.

A. Bremer, The use of insulin in cystic fibrosis-related diabetes: A philosophical difference from the use of insulin in Type 1 and Type 2 diabetes, Pediatric Pulmonology, vol.7, issue.11, pp.1039-1080, 2012.
DOI : 10.1016/j.jcf.2008.01.004

P. Gottlieb, L. Yu, S. Babu, J. Wenzlau, M. Bellin et al., No Relation Between Cystic Fibrosis-Related Diabetes and Type 1 Diabetes Autoimmunity, Diabetes Care, vol.35, issue.8, p.57, 2012.
DOI : 10.2337/dc11-2327

URL : http://europepmc.org/articles/pmc3402258?pdf=render

M. Costa, S. Potvin, Y. Berthiaume, L. Gauthier, A. Jeanneret et al., Diabetes: a major co-morbidity of cystic fibrosis, Diabetes & Metabolism, vol.31, issue.3, pp.221-253, 2005.
DOI : 10.1016/S1262-3636(07)70189-1

J. Robert, Diabète de la mucoviscidose, mt pédiatrie, vol.8, 2005.

M. Couce, O. Brien, T. Moran, A. Roche, P. Butler et al., Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis, J. Clin. Endocrinol. Metab, vol.81, pp.1267-72, 1996.

C. Huang, L. Haataja, T. Gurlo, A. Butler, X. Wu et al., Induction of endoplasmic reticulum stress-induced ??-cell apoptosis and accumulation of polyubiquitinated proteins by human islet amyloid polypeptide, American Journal of Physiology-Endocrinology and Metabolism, vol.293, issue.6, pp.1656-62, 2007.
DOI : 10.1016/S0014-5793(99)00894-7

C. Koch, H. Cuppens, M. Rainisio, U. Madessani, H. Harms et al., European Epidemiologic Registry of Cystic Fibrosis (ERCF): Comparison of major disease manifestations between patients with different classes of mutations, Pediatric Pulmonology, vol.122, issue.1, pp.1-12, 2001.
DOI : 10.1001/archotol.1996.01890230055011

S. Lanng, B. Thorsteinsson, F. Pociot, M. Marshall, H. Madsen et al., Diabetes mellitus in cystic fibrosis: genetic and immunological markers, Acta Paediatrica, vol.144, issue.2, pp.150-154, 1993.
DOI : 10.1007/BF00456124

S. Derbel, C. Doumaguet, D. Hubert, H. Mosnier-pudar, S. Grabar et al., Calpain 10 and development of diabetes mellitus in cystic fibrosis, Journal of Cystic Fibrosis, vol.5, issue.1, pp.47-51, 2006.
DOI : 10.1016/j.jcf.2005.09.011

A. Moran, P. Diem, D. Klein, M. Levitt, and R. Robertson, Pancreatic endocrine function in cystic fibrosis, The Journal of Pediatrics, vol.118, issue.5, pp.715-738, 1991.
DOI : 10.1016/S0022-3476(05)80032-0

M. Hillman, L. Eriksson, L. Mared, K. Helgesson, and M. Landin-olsson, Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus, Journal of Cystic Fibrosis, vol.11, issue.2, pp.144-153, 2012.
DOI : 10.1016/j.jcf.2011.11.001

V. Figueroa, C. Milla, E. Parks, S. Schwarzenberg, and A. Moran, Abnormal lipid concentrations in cystic fibrosis, The American Journal of Clinical Nutrition, vol.14, issue.6, pp.1005-1016, 2002.
DOI : 10.1016/S0002-9149(98)00953-9

S. Schwarzenberg, W. Thomas, T. Olsen, T. Grover, D. Walk et al., Microvascular Complications in Cystic Fibrosis-Related Diabetes, Diabetes Care, vol.30, issue.5, pp.1056-61, 2007.
DOI : 10.2337/dc06-1576

C. Koch, M. Rainisio, U. Madessani, H. Harms, M. Hodson et al., Presence of cystic fibrosis???related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: Data from the European Epidemiologic Registry of Cystic Fibrosis, Pediatric Pulmonology, vol.32, issue.5, pp.343-50, 2001.
DOI : 10.1002/ppul.1142

C. Milla, W. Warwick, and A. Moran, Trends in Pulmonary Function in Patients with Cystic Fibrosis Correlate with the Degree of Glucose Intolerance at Baseline, American Journal of Respiratory and Critical Care Medicine, vol.120, issue.3, pp.891-896, 2000.
DOI : 10.1164/ajrccm/137.1.162

A. Moran, J. Phillips, and C. Milla, Insulin and Glucose Excursion Following Premeal Insulin Lispro or Repaglinide in Cystic Fibrosis-Related Diabetes, Diabetes Care, vol.24, issue.10, pp.1706-1716, 2001.
DOI : 10.2337/diacare.24.10.1706

A. Moran, P. Pekow, P. Grover, M. Zorn, B. Slovis et al., Insulin Therapy to Improve BMI in Cystic Fibrosis-Related Diabetes Without Fasting Hyperglycemia: Results of the Cystic Fibrosis Related Diabetes Therapy Trial, Diabetes Care, vol.32, issue.10, pp.1783-1791, 2009.
DOI : 10.2337/dc09-0585

O. Riordan, S. Robinson, P. Donaghue, K. Moran, and A. , Management of cystic fibrosis-related diabetes, Pediatric Diabetes, vol.106, issue.Suppl. 1, pp.338-382, 2008.
DOI : 10.1097/01.AOG.0000172421.04007.74

N. Scheuing, K. Badenhoop, M. Borkenstein, K. Konrad, E. Lilienthal et al., Why is insulin pump treatment rarely used in adolescents and young adults with cystic fibrosis-related diabetes? Pediatr Diabetes, 2014.

D. Hardin, J. Rice, M. Rice, and R. Rosenblatt, Use of the insulin pump in treat cystic fibrosis related diabetes, Journal of Cystic Fibrosis, vol.8, issue.3, pp.174-182, 2009.
DOI : 10.1016/j.jcf.2008.12.001

E. Mozzillo, A. Franzese, G. Valerio, A. Sepe, D. Simone et al., One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements, Pediatric Diabetes, vol.147, issue.Suppl. 2, pp.162-169, 2009.
DOI : 10.1007/BF03345538

L. Dobson, A. Hattersley, S. Tiley, S. Elworthy, P. Oades et al., Clinical improvement in cystic fibrosis with early insulin treatment, Archives of Disease in Childhood, vol.87, issue.5, pp.430-431, 2002.
DOI : 10.1136/adc.87.5.430

A. Adler, B. Shine, P. Chamnan, C. Haworth, and D. Bilton, Genetic Determinants and Epidemiology of Cystic Fibrosis-Related Diabetes: Results from a British cohort of children and adults, Diabetes Care, vol.31, issue.9, pp.1789-94, 2008.
DOI : 10.2337/dc08-0466

S. Blackman, S. Hsu, S. Ritter, K. Naughton, F. Wright et al., A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis, Diabetologia, vol.359, issue.13, pp.1858-65, 2009.
DOI : 10.1186/1479-7364-2-1-67

M. Weedon, The importance of TCF7L2, Diabetic Medicine, vol.8, issue.10, pp.1062-1068, 2007.
DOI : 10.1086/367923

S. Tofé, J. Moreno, L. Máiz, M. Alonso, H. Escobar et al., Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis, European Journal of Endocrinology, vol.21, issue.5, pp.241-248, 2005.
DOI : 10.1054/clnu.2002.0561

S. Lanng, M. Schwartz, B. Thorsteinsson, and C. Koch, Endocrine and exocrine pancreatic function and the ??F508 mutation in cystic fibrosis, Clinical Genetics, vol.85, issue.727, pp.345-353, 1991.
DOI : 10.1056/NEJM199011293232203

M. Solomon, D. Wilson, M. Corey, D. Kalnins, J. Zielenski et al., Glucose intolerance in children with cystic fibrosis, The Journal of Pediatrics, vol.142, issue.2, pp.128-160, 2003.
DOI : 10.1067/mpd.2003.5

H. Eigen, H. Bieler, D. Grant, C. K. Terrill, D. Heilman et al., Spirometric Pulmonary Function in Healthy Preschool Children, American Journal of Respiratory and Critical Care Medicine, vol.122, issue.3, pp.619-642, 2001.
DOI : 10.1164/ajrccm.160.3.9811025

A. Horsley, Lung clearance index in the assessment of airways disease, Respiratory Medicine, vol.103, issue.6, pp.793-802, 2009.
DOI : 10.1016/j.rmed.2009.01.025

P. Aurora, P. Gustafsson, A. Bush, A. Lindblad, C. Oliver et al., Multiple breath inert gas washout as a measure of ventilation distribution in children with cystic fibrosis, Thorax, vol.59, issue.12, pp.1068-73, 2004.
DOI : 10.1136/thx.2004.022590

S. Lanng, B. Thorsteinsson, J. Nerup, and C. Koch, Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis, European Journal of Pediatrics, vol.727, issue.Suppl 1, pp.684-691, 1992.
DOI : 10.1007/BF01957574

C. Bizzarri, E. Montemitro, S. Pedicelli, S. Ciccone, F. Majo et al., Glucose tolerance affects pubertal growth and final height of children with cystic fibrosis, Pediatric Pulmonology, vol.151, issue.2, 2014.
DOI : 10.1530/eje.0.151U109

M. Cheung, N. Bridges, S. Prasad, J. Francis, S. Carr et al., Growth in children with cystic fibrosis-related diabetes, Pediatric Pulmonology, vol.90, issue.12, pp.1223-1228, 2009.
DOI : 10.1002/ppul.21127

D. Wood, A. Brennan, B. Philips, and E. Baker, Effect of hyperglycaemia on glucose concentration of human nasal secretions, Clinical Science, vol.106, issue.5, pp.527-560, 2004.
DOI : 10.1042/CS20030333

B. Philips, J. Redman, A. Brennan, D. Wood, R. Holliman et al., Glucose in bronchial aspirates increases the risk of respiratory MRSA in intubated patients, Thorax, vol.60, issue.9, pp.761-765, 2005.
DOI : 10.1136/thx.2004.035766

A. Brennan, K. Gyi, D. Wood, J. Johnson, R. Holliman et al., Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis, Journal of Cystic Fibrosis, vol.6, issue.2, pp.101-110, 2007.
DOI : 10.1016/j.jcf.2006.03.009

S. Lanng, B. Thorsteinsson, J. Nerup, and C. Koch, Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections, Acta Paediatrica, vol.82, issue.8, pp.849-53, 1994.
DOI : 10.1007/BF02428297

S. Nousia-arvanitakis, A. Galli-tsinopoulou, and M. Karamouzis, Insulin improves clinical status of patients with cystic-fibrosis-related diabetes mellitus, Acta Paediatrica, vol.90, issue.5, pp.515-524, 2001.
DOI : 10.1080/080352501750197647

A. Sterescu, B. Rhodes, R. Jackson, A. Dupuis, A. Hanna et al., Natural History of Glucose Intolerance in Patients with Cystic Fibrosis: Ten-Year Prospective Observation Program, The Journal of Pediatrics, vol.156, issue.4, pp.613-620, 2010.
DOI : 10.1016/j.jpeds.2009.10.019

O. Riordan, S. Robinson, P. Donaghue, K. Moran, and A. , Management of cystic fibrosis-related diabetes in children and adolescents, Pediatric Diabetes, vol.106, issue.Suppl1 OP 32, 0, pp.43-50, 2009.
DOI : 10.1097/01.AOG.0000172421.04007.74

O. Riordan, S. Hindmarsh, P. Hill, N. Matthews, D. George et al., Validation of Continuous Glucose Monitoring in Children and Adolescents With Cystic Fibrosis: A prospective cohort study, Diabetes Care, vol.32, issue.6, pp.1020-1022, 2009.
DOI : 10.2337/dc08-1925

S. Hameed, J. Morton, A. Jaffé, P. Field, Y. Belessis et al., Early Glucose Abnormalities in Cystic Fibrosis Are Preceded by Poor Weight Gain, Diabetes Care, vol.33, issue.2, pp.221-227, 2010.
DOI : 10.2337/dc09-1492

URL : http://care.diabetesjournals.org/content/diacare/33/2/221.full.pdf

A. Leclercq, B. Gauthier, V. Rosner, L. Weiss, F. Moreau et al., Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients, Journal of Cystic Fibrosis, vol.13, issue.4, 2013.
DOI : 10.1016/j.jcf.2013.11.005